Interleukin-2 in the treatment of malignant melanoma

Bibliography

• BALCH CM, REINTGEN DS, KIRKWOOD JM et al: Cutane- ous melanoma. In: Cancer, Principles and Practice of On-cology. Devita VT, Hellman S, Rosenberg SA (Eds.), Lippincott-Raven, Philadelphia, PA, USA (1997):1947–1994.
   Google Scholar
• KEILHOLZ U, SCHEIBENBOGEN C, STOELBEN E et al.: Im-munotherapy of metastatic melanoma with inter-feron-a and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur. J. Cancer (1994) 30A:955-958. A30.
   PubMedGoogle Scholar
• HENDERSON-BAKAS M, DAVIS C, POO W-J: Prolonged survival in patients with advanced melanoma after chemotherapy and resection. Proc. Am. Soc. Clin. Oncol (1994) 13:397
   Google Scholar
• FRANK S, RELLMANN R, APPLEWHITE J et al.: Predictors of long-term survival in stage IV melanoma. Proc. Am. Soc. Clin. Oncol (1995) 14:411.
   Google Scholar
• PETIT T, BOREL C, RIXE O et al.: Complete remission seven years after treatment for metastatic malignant melanoma. Cancer (1996) 77:900–902.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, RING S, PAPADOPOULOS N et al. A prospec- tive evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 64:2024–2029.
   PubMed Web of Science ®Google Scholar
• HILL, GJ, II, KREMENTZ ET, HILL HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer (1984) 53:1299–1305.
   PubMed Web of Science ®Google Scholar
• AHMANN DL, CREAGAN ET, HAHN RG et al.: Complete responses and long-term survival after systemic che-motherapy for patients with advanced malignant melanoma. Cancer (1989) 63:224–227.
   PubMed Web of Science ®Google Scholar
• COATES AS, SEGELOV E: Long-term response to chemo-therapy in patients with visceral metastatic mela-noma. Ann. Oncol (1994) 5:249–251.
   PubMed Web of Science ®Google Scholar
• LEGHA S, RING S, ETON O et al: Durable complete re-sponses (CRs) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and IL-2 + interferon-alpha (IFN-ocA) in the treat-ment of disseminated malignant melanoma. Cancer (1986) 58:2576–2578.
   PubMedGoogle Scholar
• BERD D, MASTRANGELO MJ: Combination chemother-apy of metastatic melanoma. J. Clin. Oncol (1995) 13:796.
   PubMed Web of Science ®Google Scholar
• CREAGAN ET, AHMANN DL, FRYTAK S et al: Recombi-nant leukocyte A interferon (rIEN-ocA) in the treatment of disseminated malignant melanoma. Cancer (1986) 58:2576–2578.
   PubMedGoogle Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL etal.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271:907–913.
   Google Scholar
• LOWES MA, BISHOP GA, CROTTY K et al.: T-helper 1 cy-tokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol (1997) 108:914–919.
   PubMed Web of Science ®Google Scholar
• DEVRIES JE, SPITS H: (CTL) Cloned human cytotoxic T lymphocyte lines reactive with autologous melanoma cells. J. Immunol (1984) 132:510–519.
   PubMedGoogle Scholar
• COX AL, SKIPPER J, CHEN Y et al: Identification of a pep-tide recognized by five melanoma-specific human cy-totoxic T cell lines. Science (1994) 264:716–719.
   PubMed Web of Science ®Google Scholar
• PLAISANCE S, RUBINSTEIN E, ALILECHE A et al.: Human melanoma cells express a functional interleukin-2. Int. J. Cancer (1993) 55:164–170.
   PubMed Web of Science ®Google Scholar
• WEIDMANN E, BERGMANN L, STOCK J et al.: Rapid cyto-kine release in cancer patients treated with interleukin-2. j Immunother. (1992) 122:123–131.
   Google Scholar
• BAARS JW, WOLBINK GJ, HART MH et al.: The release of interleukin-8 during intravenous bolus treatment with interleukin-2. Ann. Oncol. (1994) 5:929–934.
   PubMed Web of Science ®Google Scholar
• DEEHAN DJ, HEYS SD, SIMPSON WG et al: In vivo cyto-kine production and recombinant interleukin-2 im-munotherapy: an insight into the possible mechanisms underlying clinical responses. Br. J. Can-cer (1994) 69:1130–1335.
   PubMed Web of Science ®Google Scholar
• BAARS JW, HACK CE, WAGSTAFF J et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br. J. Cancer (1992) 65:96–101.
   PubMed Web of Science ®Google Scholar
• DUBOIS JS, TREHN EG, MIER JW et al: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol (1997) 15:1052–1062.
   PubMed Web of Science ®Google Scholar
• SALVO G, SAMOGGIA P, MASCIULLI R etal.: Interleukin-2 bolus therapy induces immediate and selective disap-pearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium. Eur J. Cancer (1992) 4–5:818-825. Abstract A28.
   Google Scholar
• SIEGEL JP: Pharmacokinetics of lymphocyte-derived and recombinant DNA derived interleukin-2 after in-travenous administration to patients with the ac-quired immune deficiency syndrome. J. Biol. Resp. Modifiers (1985) 4:596–601.
   PubMedGoogle Scholar
• MASUCCI G, SVENSSON A, HANSSON M et al.: Efficient harvest of in vivo 11-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytopheresis). j Hematother. (1997) 6:253–260.
   PubMedGoogle Scholar
• VLASVELD LT, HEKMAN A, VYTH-DREESE FA et al.: A Phase I study of prolonged continuous infusion of low-dose recombinant interleukin-2 in melanoma and renal cell cancer. PART II: immunological aspects. Br. J. Cancer (1993) 68:559–567.
   Google Scholar
• MCKENZIE RS, SIMMS PE, HELFRICH BA et al.: Identifica-tion of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin-2. Cancer Res. (1992) 52:6318–6322.
   PubMed Web of Science ®Google Scholar
• BECKER JC, DUMMER R, SCHWINN A, HARTMANN AA, BURG G: Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy. J. Immunother. (1992) 12(2):147–150.
   PubMed Web of Science ®Google Scholar
• MAZUMDER A, ROSENBERG SA: Successful immuno-therapy of natural killer-resistant established pulmo-nary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J. Exp. Med. (1984) 159:495–507.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, MULE JS, SPEISS PJ et al.: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Merl. (1985) 161:1169–1188.
   PubMed Web of Science ®Google Scholar
• MULE JJ, SHU S, SCHWARTZ SL et al.: Successful adoptive immunotherapy of established pulmonary metastases of multiple sarcomas with lymphokine-activated killer cells and recombinant interleukin-2. Science (1984) 225:1487–1489.
   PubMed Web of Science ®Google Scholar
• MERTENS WC, BANERJEE D, AL-MUTTER N et al.: High-dose continuous venous infusion of interleukin-2: in-fluence of dose and infusion rate on tumoricidal func-tion and lymphocyte subsets. Cancer Immunol. Immunother. (1995) 41:271–279.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA LOTZE MT, YANG J et al.: Experience with the use of high-dose interleukin-2 in the © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(3) treatment of 652 cancer patients. Ann. Surg. (1989) 210:474–485.
   Google Scholar
• THOMPSON JA, LEE DJ, LINDGREN CG et al.: Influence of dose and duration of infusion of interleukins on toxic-ity and immunomodulation. j Clin. Oncol. (1988) 6:669–678.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, MULE JS, SPEISS PJ et al.: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J. Exp. Med. (1985) 161:1169–1188.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA (1994) 271(12)907–913.
   Google Scholar
• PARKINSON DR, ABRAMS JS, WIERNIK PH et al.: Interleukin-2 therapy in patients with metastatic ma-lignant melanoma: a Phase II study. J. Clin. Oncol. (1990) 8(10):1650–1656.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD RP, KOPECKY KJ, SAMSON MK et al: Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group Study. JNCI (1991) 83 (17) :1250–1252.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, FISHER RI, SUNDERLAND M et al.: Random-ized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with in-terferon alpha-2a in patients with advanced mela-noma. J. Clin. Oncol. (1993) 11 (10) :1969–1977.
   PubMed Web of Science ®Google Scholar
• HERSH EM, MURRAY JL, HONG WK eta].: Phase I study of cancer therapy with recombinant interleukin-2 ad-ministered by intravenous bolus injection. Biotherapy (1989) 1:215–216.
   Google Scholar
• DEMCHAK PA, MIER JW, ROBERT NJ et al.: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J. Clin. Oncol (1991) 9:1821–1830.
   PubMed Web of Science ®Google Scholar
• SZNOL M A, PARKINSON DR: Clinical applications of IL-2. Oncology (1994) 8(6):61–75.
   PubMedGoogle Scholar
• GULERIA AS, YANG JC, TOPALIAN SL et al.: Renal dys-function associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J. Clin. On-col. (1994) 12:2714–2722.
   PubMed Web of Science ®Google Scholar
• WHITE RL, SCHWARTZENTRUBER DJ, GULERIA A et al.: Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer (1994) 74:3212–3222.
   PubMed Web of Science ®Google Scholar
• CORMIER JN, HURST R, VASSELLI J, LEE D et al.: A pro-spective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. j Immunother. (1997) 20:292–300.
   PubMed Web of Science ®Google Scholar
• THOMPSON JA, LEE DJ, LINDGREN CG et al.: Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine activated killer cells. Cancer Res. (1989) 49:235–240.
   PubMed Web of Science ®Google Scholar
• VLASVELD LT, RANKIN EM, HEKMAN A et al.: A Phase Istudy of prolonged continuous infusion of low-dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. Br. J. Cancer (1992) 65:744–750.
   Google Scholar
• WEST WH, TAUER KW, YANELLI JR et al: Constant-infusion IL-2 recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl. J. Med. (1987) 316:898–905.
   PubMed Web of Science ®Google Scholar
• RICHARDS JM, BAJORIN DF, VOGELZANG NJ eta].: Treat-ment of metastatic melanoma with continuous intra-venous IL-2 ± LAK cells: a randomized trial. Proc. Am. Soc. Clin. Oncol (1990) 9:279.
   Google Scholar
• DUTCHER JP, GAYNOR ER, BOLDT DH et al.: A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J. Gun. Oncol. (1991) 9(4) 641–648.
   Web of Science ®Google Scholar
• CREEKMORE SP, HARRIS JE, ELLIS TM et al: A Phase I study of high-dose continuous infusion interleukin-2 by periodic 24 hour intravenous infusions. J. Clin. On-col. (1989) 7:276–284.
   PubMed Web of Science ®Google Scholar
• VLASVELD LT, HORENBLAS S, HEKMAN A et al.: Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancers. Ann. Oncol (1994) 5 (2) :179–181.
   PubMed Web of Science ®Google Scholar
• PEREZ EA, SCUDDER SA, MEYERS FA et al.: Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a Phase I study. J. Immunother. (1991) 10:57–62.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, OLDHAM RK, TAUER KW et al: Continuousinterleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group Trial. J. Clin. Oncol. (1991) 9:1233–1240.
   PubMed Web of Science ®Google Scholar
• DORVAL T, MATHIOT C, CHOSIDOW O et al.: rIL-2 PhaseII trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol. Ther. (1992) 3:63–79.
   PubMedGoogle Scholar
• LEGHA SS, GIANAN MA, PLAGER C et al.: Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer (1996) 77(1):89–96.
   PubMed Web of Science ®Google Scholar
• SONDEL PM, KOHLER PC, HANK JA eta].: Clinical and im-munological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with can-cer. Cancer Res. (1988) 48:2561–2573.
   Google Scholar
• ROSENBERG SA, SPIESS P, LAFRENIERE R: A new ap-proach to adoptive immunotherapy of cancer with tu-mor infiltrating lymphocytes. Science (1986) 233:1318–1321.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, PACKARD BS, AEBERSOLD PM et al.: Useof tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic mela-noma: a preliminary report. New Engl. J. Med. (1988) 319:1676–1680.
   PubMed Web of Science ®Google Scholar
• KRADIN RL, KURNICK JT, LAZARUS DS et al.: Tumor-infiltrating lymphocytes and interleukin-2 in treat-ment of advanced cancer. Lancet (1989) 1:577–580.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. JNCI (1994) 86(15):1159–1166.
   PubMed Web of Science ®Google Scholar
• GOEDEGEBUURE PS, DOUVILLE LM, LI H et al.: Adoptiveimmunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malig-nant melanoma and renal cell carcinoma: a pilot study. J. Gun. Oncol. (1995) 13:1939–1949.
   Web of Science ®Google Scholar
• SCHWARTZENTRUBER DJ, HOM SS, DADMARZ R et al.: Invitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. j Gun. Oncol. (1994) 12 (7) :1475–1483.
   Web of Science ®Google Scholar
• LAFRENIERE R, ROSENBERG SA: Successful immuno-therapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombi-nant interleukin-2. Cancer Res. (1985) 45:3735–3741.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, PACKARD BS, AEBERSOLD PM etal.: Useof tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic mela-noma. New Engl. J. Med. (1988) 319:1677–1680.
   Google Scholar
• BAR MH, SZNOL M, ATKINS MB et al: Metastatic malig-nant melanoma treated with combined bolus and con-tinuous infusion interleukin-2 and lymphokine-activated killer cells. J. Gun. Oncol. (1990) 8:1138–1147.
   Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC et al. Prospective, randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI (1993) 85:622–631.
   PubMed Web of Science ®Google Scholar
• SZNOL M, DUTCHER JP, ATKINS MB et al. Review of interleukin-2 alone and interleukin-2/LAK clinical tri-als in metastatic malignant melanoma. Cancer Treat. Rev. (1989) 16(Suppl A) 29–38
   Google Scholar
• LEGHA SS: The role of interferon alpha in the treat-ment of metastatic melanoma. Semin. Onc. (1997) 24(1 Suppl 4):524–31.
   Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. (1989) 7:1863–1874.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, MICETICH KC, SUNDERLAND M: A random-ized Phase III trial of treatment with high-dose interleukin-2 (rIL-2) either alone or in combination with interferon alpha 2a (rIFIs) in patients with ad-vanced melanoma. Proc. Am. Soc. Clin. Oncol. (1993) 12:A1332.
   Google Scholar
• LEGHA SS: Durable complete responses in metastaticmelanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin. On-col. (1997) 24 (Suppl 4):539–43.
   Google Scholar
• THOMPSON JA, GOLD PJ, FEFER A: Outpatient chemo-immunotherapy for the treatment of metastatic mela-noma. Semin. Oncol. (1997) 24 (Suppl. 4):544–8.
   Google Scholar
• ATZPODIEN J, LOPEZ HANNINEN E, KIRCHNER H et al.: Chemoimmunotherapy of advanced malignant mela-noma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarba-zine, cisplatin, carmustine and tamoxifen. Eur. J. Can-cer (1995) 31A:876–881.
   PubMed Web of Science ®Google Scholar
• MARINCOLA FM, VENZON D, WHITED etal.: HLA associ-ated with response and toxicity in melanoma patients treated with interleukin-2 based immunotherapy. Cancer Res. (1992) 52:6561–6566.
   Google Scholar
• RUBIN JT, DAY R, DUQUESNOY R et al: HLA-DQI is asso-ciated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther. Immunol. (1995) 2:1–6.
   PubMedGoogle Scholar
• DILLMAN RO, OLDHAM RK, BARTH NM et al.: Continuous interleukin-2 and tumor infiltrating lymphocytes in treatment of advanced melanoma: a national biother-apy study group trial. Cancer (1991) 68:1–8.
   PubMed Web of Science ®Google Scholar
• SCHNEEKLOTH C, KORFER A, HADAM M et al.: Low-dose interleukin-2 in combination with interferon-alpha ef-fectively modulates biological response in vivo. Acta Haematol. (1993) 89:13–21.
   PubMed Web of Science ®Google Scholar
• RUBIN JT, ELWOOD LJ, ROSENBERG SA et al.: Immuno-histochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Can-cer Res. (1989) 49:7086–7092.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, MIER JW, PARKINSON DR et al.: Hypothy-roidism after treatment with interleukin-2 and lymphokine-activated killer cells. New Engl. J. Med. (1988) 318:1557–1563.
   PubMed Web of Science ®Google Scholar
• DEEHAN DJ, HEYS SD, SIMPSON WG et al.: In vivo cyto-kine production and recombinant interleukin-2 im-munotherapy: an insight into the possible mechanisms underlying clinical responses. Br. J. Can-cer (1994) 69:1130–1135.
   PubMed Web of Science ®Google Scholar
• TARTOUR E, BLAY JY, DORVAL T et al.: Predictors of clinical response to interleukin-2-based immunother-apy in melanoma patients: a French multi-institutional study. J. Clin. Oncol (1996) 14:1697–1703.
   PubMed Web of Science ®Google Scholar
• BLAY JY, FAVROT MC, NEGRIER S et al: Correlation be-tween clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res. (1990) 50:2371–2374.
   PubMed Web of Science ®Google Scholar